---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-252984"
form_type: "8-K"
ticker: "OKUR"
cik: "0001637715"
company_name: "OnKure Therapeutics, Inc."
filed_at: "2023-10-10T23:59:59+00:00"
generated_at: "2026-06-10T02:27:28.374114+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Reneo Pharma announces last patient last visit in pivotal STRIDE study; topline data expected Dec 2023

## Summary
- Last patient last visit completed in STRIDE study of mavodelpar for primary mitochondrial myopathies; topline data expected December 2023.
- Over 85% of eligible patients enrolled in ongoing STRIDE AHEAD study.
- Company to share data analysis with FDA in Q1 2024; NDA submission planned first half 2024.
- STRIDE and STRIDE AHEAD studies to form basis of NDA submission to FDA and other regulators.

## SEC filing metadata
- accession: 0001193125-23-252984
- form_type: 8-K
- ticker: OKUR
- cik: 0001637715
- company_name: OnKure Therapeutics, Inc.
- filed_at: 2023-10-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1637715/000119312523252984/0001193125-23-252984-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1637715/000119312523252984/d535917d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-252984
- JSON: https://secwatch.observer/filing/0001193125-23-252984.json
- Plain text: https://secwatch.observer/filing/0001193125-23-252984.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.